2-acetylamino-4-methanesulfonyloxymethylpyridine | 864461-12-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-acetylamino-4-methanesulfonyloxymethylpyridine
• 英文别名: 2-acetamido-4-methanesulfonyloxymethylpyridine；(2-acetamidopyridin-4-yl)methyl methanesulfonate
• CAS: 864461-12-1
• 化学式: C₉H₁₂N₂O₄S
• 分子量: 244.271
• InChiKey: FTSKPDRJYQOEFE-UHFFFAOYSA-N

物化性质

• 沸点：
  555.5±45.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-巯基烟酸 、 2-acetylamino-4-methanesulfonyloxymethylpyridine 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以66%的产率得到2-(2-acetamidopyridin-4-yl)methylthionicotinic acid
  参考文献：
  名称：

  EP2128156

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(4-(hydroxymethyl)pyridin-2-yl)acetamide 、 甲基磺酰氯 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.1h， 生成 2-acetylamino-4-methanesulfonyloxymethylpyridine
  参考文献：
  名称：

  Novel HIV reverse transcriptase inhibitors

  摘要：

  这项发明涉及到以下化合物的公式(I)、(II)或(III)： 或其药用可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法。

  公开号：

  US20080070920A1

文献信息

• NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY
  申请人：Honda Takahiro

  公开号：US20100016354A1

  公开（公告）日：2010-01-21

  The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; R a represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B represents a pyridine ring, a pyrimidine ring, or a quinoline ring; the ring C represents a benzene ring; a pyridine ring, a quinoline ring, or an isoquinoline ring; X and Y, the same or different, represent an oxygen atom or a sulfur atom, with the proviso that the case X is a sulfur atom and Y is an oxygen atom be excluded; R 1 represents a hydrogen atom, a halogen atom, an amino group, a cycloalkylamino group, an alkylcarbonylamino group, an alkyloxycarbonylamino group, an alkylaminocarbonyl group, or a non-aromatic heterocyclic group; and R 2 and R 2 ′, the same or different, represent a hydrogen atom, a halogen atom, an alkyl group, a halogeno-alkyl group, or a halogeno-alkoxy group.

  本发明涉及由式（I）表示的化合物或其盐。在式（I）中，环A表示苯环，噻吩环或吡啶环；R表示氢原子，卤素原子，烷基或烷氧基；环B表示吡啶环，嘧啶环或喹啉环；环C表示苯环，吡啶环，喹啉环或异喹啉环；X和Y，相同或不同，表示氧原子或硫原子，但X是硫原子且Y是氧原子的情况除外；R1表示氢原子，卤素原子，氨基，环烷基氨基，烷基羰基氨基，烷氧羰基氨基，烷基氨基甲酰基或非芳香族杂环基；而R2和R2'，相同或不同，表示氢原子，卤素原子，烷基，卤代烷基或卤代烷氧基。
• Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Honda Takahiro

  公开号：US20070149574A1

  公开（公告）日：2007-06-28

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R 1 and R 2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R 3 and R 4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R 5 , etc.; R 5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR 6 —, —SO 2 —, etc.; R 6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种具有4-吡啶基烷基硫基团的新型环状化合物，其中引入了（未）取代氨基或其盐。它们可用作药物。环状化合物是由以下式（1）表示的化合物，可用于治疗参与血管生成的疾病。在下式（1）中，环A表示苯环或5-或6-成员芳香杂环，可选择地与环烷环融合；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示-CO-，-COO-，-CONR6-，-SO2-等；R6表示H等；p为0、1或2；q为0或1。
• Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US07544703B2

  公开（公告）日：2009-06-09

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR6—, —SO2—, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种新型环状化合物，具有4-吡啶基烷基硫基团，其中引入了（未）取代氨基或其盐。它们可用作药物。该环状化合物是由以下式（1）表示的化合物，对参与血管生成的疾病的治疗有用。在以下式（1）中，环A表示苯环或可选地与环烷环融合的5或6成员芳香杂环；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示—CO—，—COO—，—CONR6—，—SO2—等；R6表示H等；p为0、1或2；q为0或1。
• NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY
  申请人：Santen Pharmaceutical Co., Ltd

  公开号：EP2128156A1

  公开（公告）日：2009-12-02

  The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; Ra represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B represents a pyridine ring, a pyrimidine ring, or a quinoline ring; the ring C represents a benzene ring, a pyridine ring, a quinoline ring, or an isoquinoline ring; X and Y, the same or different, represent an oxygen atom or a sulfur atom, with the proviso that the case X is a sulfur atom and Y is an oxygen atom be excluded; R1 represents a hydrogen atom, a halogen atom, an amino group, a cycloalkylamino group, an alkylcarbonylamino group, an alkyloxycarbonylamino group, an alkylaminocarbonyl group, or a non-aromatic heterocyclic group; and R2 and R2', the same or different, represent a hydrogen atom, a halogen atom, an alkyl group, a halogeno-alkyl group, or a halogeno-alkoxy group.

  本发明涉及式（I）所代表的化合物或其盐类。在式 (I) 中，环 A 代表苯环、噻吩环或吡啶环；Ra 代表氢原子、卤素原子、烷基或烷氧基；环 B 代表吡啶环、嘧啶环或喹啉环；环 C 代表苯环、吡啶环、喹啉环或异喹啉环；X 和 Y 相同或不同，代表氧原子或硫原子，但不包括 X 为硫原子而 Y 为氧原子的情况；R1 代表氢原子、卤素原子、氨基、环烷基氨基、烷基羰基氨基、烷氧基羰基氨基、烷基氨基羰基或非芳香杂环基团；R2 和 R2'相同或不同，代表氢原子、卤素原子、烷基、卤代烷基或卤代烷氧基。
• NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1717229B1

  公开（公告）日：2011-06-15